Canadian healthcare company Nuvo Pharmaceuticals has completed the previously announced acquisition of a portfolio of more than 20 revenue-generating products from Aralez Pharmaceuticals.
Opiant Pharmaceuticals has signed a licensing agreement with Sanofi for the development and commercialisation of drinabant across the globe for the treatment of acute cannabinoid overdose (ACO).
Taisho Pharmaceutical has offered $1.6bn to acquire UPSA consumer health business from Bristol-Myers Squibb (BMS).
Circassia Pharmaceuticals is set to exercise an option to purchase full US commercial rights of chronic obstructive pulmonary disease treatment, Tudorza (aclidinium), from AstraZeneca.
Crown Laboratories, a privately held, fully integrated global skin care company, has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK).
AstraZeneca has agreed to offload the US rights of its respiratory drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) in a cash-cum-stock deal worth $1.5bn.
Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for a sum of up to $32m, which includes contingent payments of up to $17m based on commercial milestones and other factors.
Johnson & Johnson (J&J) has agreed to acquire all outstanding shares of Japanese skincare firm, Ci:z Holdings, in a deal valued at around ¥230bn ($2.04bn).
Dova Pharmaceuticals, Salix Pharmaceuticals and its parent company Bausch Health Companies have entered into an exclusive agreement to co-promote Dova’s Doptelet (avatrombopag) in the US.
Shield Therapeutics and Norgine have entered into an exclusive licence agreement in Europe, Australia and New Zealand, under which Norgine will commercialise Feraccru, Shield’s approved product for the treatment of iron deficiency in adults.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.